相关实验视频

Updated: May 5, 2026

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

专题:针对血液恶性病的抗体疗法

Jonathan P Butchar¹

¹Division of Hematology, The Ohio State University Wexner Medical Center, 410 W, 12th Avenue, Columbus, OH 43210, USA.

International journal of molecular sciences

|October 16, 2025

概括

血液性恶性瘤占所有癌症的6%. 需要进一步的研究,以了解这些血液癌症的具体特征和治疗结果.

科学领域:

在瘤学瘤学.
血液学血液学血液学

背景情况:

血液性恶性瘤是源于血液细胞的癌症.
这些癌症占总体癌症诊断的很大一部分.

研究的目的:

为了突出血液性恶性瘤的流行.
要强调需要在这个领域继续进行研究.

主要方法:

审查最近的癌症统计数据.
对流行病学数据的分析.

主要成果:

血液恶性瘤占所有报告的癌症病例的6%.
这表明血相关癌症的发病率显著.

结论:

血液性恶性瘤是癌症的一个重要群体.
需要进一步研究它们的特定亚型,风险因素和治疗策略.

更多相关视频

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells

Published on: November 12, 2019

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

相关概念视频

Humoral Immune Responses

Humoral Immune Responses

Cross-reactivity

Cross-reactivity

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Hypersensitivity Reactions: Cytolytic Reactions

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...